InspireMD, Inc. (NSPR) Form 10-Q — Aug 14, 2026
InspireMD's 10-Q for the quarter ended June 30, 2026 states there is substantial doubt about the Company's ability to continue as a going concern. The company held $15.1 million in cash plus $15.3 million in marketable securities against a $28.0 million first-half net loss and $23.2 million of operating cash burn, and says it must raise capital through equity, debt, partnerships, or warrant exercises to fund operations. InspireMD received a Nasdaq notification letter on July 17, 2026 for trading below the $1.00 minimum bid price requirement. The stock closed at $0.8401 on August 13, 2026, and the company has until January 13, 2027 to regain compliance or face potential delisting.
Key figures
- Revenue
- 1771000
- Revenue Yoy
- -0.4% (Q2 2026 vs Q2 2025); +56.3% (H1 2026 vs H1 2025)
- Cash Position
- 15149000
- Shares Outstanding
- 46489118
- H1 2026 revenue
- 5169000
- Q2 gross margin
- -43.7%
- H1 2026 net loss
- 28013000
- Atm capacity btig
- 75000000
- Accumulated deficit
- 330305000
- Warrants outstanding
- 25828164
- Marketable securities
- 15272000
- Recall revenue credit
- 734000
- Warrant exercise price
- 1.3827
- Workforce reduction pct
- ~20%
- Nasdaq compliance deadline
- January 13, 2027
- Operating cash use h1 2026
- 23232000
- Addressable market estimate
- $1.3 billion
- Last sale price aug 13 2026
- 0.8401
- Recall inventory impairment
- 612000
- Workforce annualized savings
- 9000000
- Restructuring charges estimate
- $0.9M-$1.2M
- Pre funded warrants outstanding
- 43092107
- Total available market estimate
- $9.3 billion
Price after filing
Close on the filing date to close N calendar days later (from $0.98). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.